X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3%
Thu, 15 Nov

GLENMARK PHARMA has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:

GLENMARK PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Sep-17*
3
Jun-18*
3
Sep-18*
QoQ ChangeYoY Change
Net SalesRs m22,56621,65625,81319.2%14.4%
Other incomeRs m2971,3821,3991.2%370.6%
TurnoverRs m22,86323,03827,21218.1%19.0%
ExpensesRs m18,68218,18721,41217.7%14.6%
Gross profitRs m3,8843,4696,07375.1%56.4%
DepreciationRs m7527948253.9%9.6%
InterestRs m6987908517.7%21.9%
Profit before taxRs m2,7313,2675,79677.4%112.3%
TaxRs m5899371,65676.7%181.0%
Profit after taxRs m2,1412,3304,14077.7%93.3%
Gross profit margin%17.216.023.5
Effective tax rate%21.628.728.6
Net profit margin%9.410.115.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 14.4% on a year-on-year (YoY) basis. The expenses were up by 14.6% YoY during the same period.
  • The company's operating profit increased by 56.4% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.5% in 2QFY19 as against 17.2% in 2QFY18.
  • Depreciation charges increased by 9.6% and finance costs increased by 21.9% YoY, respectively.
  • Other income increased by 370.6% YoY during the quarter.
  • Net profit for the quarter increased by 93.3% YoY. Net profit margins during the quarter increased from 9.4% in 2QFY18 to 15.2% in 2QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 19.2% on a quarter-on-quarter (QoQ) basis. The expenses were up by 17.7% QoQ during the same period.
  • The company's operating profit increased by 75.1% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 23.5% in 2QFY19 as against 16.0% in 1QFY18.
  • Net profit for the quarter increased by 77.7% QoQ, while net profit margins increased from 10.1% in 1QFY18 to 15.2% in 2QFY19.

To see how GLENMARK PHARMA has performed over the last eight quarters, please visit here.

GLENMARK PHARMA Share Price Performance

Over the last one year, GLENMARK PHARMA share price has moved up from Rs 583.1 to Rs 660.7, registering a Gain of Rs 77.6 or around 13.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,195.7 (down 0.2%). Over the last one year it has moved up from 13,548.3 to 14,195.7, a gain of 647 points (up 4.8%).

Overall, the S&P BSE SENSEX is up 6.7% over the year.

Current Valuations

At the current price of Rs 660.7, the price to earnings (P/E) ratio of GLENMARK PHARMA stands at 19.8 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.5 times.

Equitymaster requests your view! Post a comment on "GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3%". Click here!

  

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 10, 2018 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS